U.S. FDA Tells India's Ranbaxy To Assess Plants

The U.S. drug regulator has asked India's Ranbaxy Laboratories to immediately assess whether its plants making drugs for the U.S. market meet standards, the Economic Times newspaper reported on Friday.

Ranbaxy, India's top drugmaker which is majority owned by Japan's Daiichi Sankyo, in December said a U.S. unit had received a warning letter from the U.S. Food and Drug Administration (FDA) on violations of good manufacturing practices. A Ranbaxy spokesman said he had no fresh comment beyond that made in a statement issued on Dec. 24 in the wake of the FDA letter, where Ranbaxy said it would cooperate with regulators and remained committed to comply with standards.

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.